How Upperton Has Evolved To Meet The Changing Needs Of Biotechs

By Richard Johnson, Chief Scientific Officer, Upperton

Over the past several decades, the role of Contract Development and Manufacturing Organizations (CDMOs) has transformed dramatically. What began as a largely transactional model—where biotechs outsourced isolated tasks—has evolved into deeply collaborative partnerships that shape development from the earliest stages. As molecules have grown more complex and regulatory expectations more demanding, CDMOs now provide strategic insight across formulation, analytical development, manufacturability, scalability, and quality planning. This shift has been driven by scientific innovation, heightened regulatory scrutiny, and the industry’s intensified focus on speed‑to‑market. Today’s CDMOs work alongside sponsors long before a formulation exists, helping anticipate risks, streamline development, and build robust, phase‑appropriate strategies that reduce delays and late‑stage setbacks. Strong project leadership and integrated cross‑disciplinary teams have become essential, as have supply‑chain resilience and sustainability. Looking ahead, CDMOs are poised to become even more interconnected partners—sharing data in real time and guiding innovators from concept to impact with greater transparency and alignment.